Page 6 - Pharmaceutical Firms

Aveo Pharma suspects misuse of painkiller Tafrodol in importing countries

The company also clarified that the "stop production" order of Feb 24 was due to compliance issues under the Schedule M of the Drugs and Cosmetics Rules, 1945, and not due to the combination product

Sun Pharma to acquire US based Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations

Biocon Biologics, Civica partner to expand Insulin Aspart access in the US

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration (FDA)

Senores Pharma to acquire 14 ANDAs from Dr Reddy's for US markets

Gujarat-based Senores Pharmaceuticals on Tuesday said it will acquire a basket of 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories for an undisclosed amount. Senores Pharmaceuticals, Inc, USA, a subsidiary of the drug firm, has inked agreements with Dr Reddy's for acquiring the Abbreviated New Drug Applications (ANDAs), the company said in a statement. The basket includes 13 ANDAs approved by the USFDA (US Food and Drug Administration), with one application pending approval, it added. The addressable opportunity of the acquired ANDAs in the US is around USD 421 million as per IQVIA. Senores said the acquisition will be funded through the initial public offer proceeds. This is in line with the objects of the IPO stated in the Red Herring Prospectus, it added. Senores Pharmaceuticals MD Swapnil Shah said the acquired molecules span multiple therapeutic areas with growing consumption. The portfolio consists of controlled substances and the general category of produ

India pharma exports surge 9%, outpacing global average, says report

India has also surpassed the US in the number of FDA-registered generic manufacturing sites

CDSCO plans to streamline drug export clearances to reduce workload

The agency has only 2,000 officials to oversee over 10,000 drug factories and 1 million pharmacies in India

Venus Remedies to co-develop antibiotic resistance blocker with UK firm

Clinical trials to start next year, and drug can be in market by 2031-32

Drugmaker Amgen to invest $200 million in India site: CEO Robert Bradway

Amgen announced its plans to open a "technology and innovation" site in India last year that is focused on increasing the use of AI and data science to support development of new medicines

Pharma sector can deliver 100 new drugs by 2047: Zydus chairman

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv

Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma

The company relies on its key generic drugs in oncology and immunology therapies for sales in the region, which rose 28 per cent from a year earlier

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

GlaxoSmithKline Pharma Q3FY25: Net profit rises 400% to Rs 228.58 crore

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024. The drug firm reported a net profit of Rs 45 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 949 crore for the third quarter, as compared to Rs 805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement. "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar stated. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added. The company saw strong performance across key product portfolios during the quarter, the drug firm said. Flagship brands within the genera

Pharma exports to touch $65 bn mark by 2030, $350 bn by 2047: Report

India's pharma exports are expected to double to USD 65 billion by 2030 and touch USD 350 billion in value terms by 2047, moving to top five position globally by diversifying its product basket, according to a report. While India is the largest supplier of generic drugs globally, accounting for one in five generic drugs sold worldwide, the nation ranks 11th in terms of export value. As per the Bain & Company's report, 'Healing the World: Roadmap for Making India a Global Pharma Exports Hub', India can potentially secure a position among the top five nations in export value by 2047 by innovating and diversifying its export basket to include specialty generics, biosimilars, and innovative products. The findings in the report were formulated in collaboration with Indian Pharmaceutical Alliance (IPA), Indian Drugs Manufacturers' Association (IDMA), and Pharmexcil. "The transition from volume-based to value-led growth is essential for Indian pharma to secure its rightful place in the ..

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

Alembic Pharma Q3 result: Profit dips 23% to Rs 138 cr on weak sales

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North American market has weighed on domestic firms' margins

Commerce Ministry withdraws 'track and trace' rule for pharma exports

The Commerce Ministry on Friday said it has withdrawn the provisions related to the track and trace system for pharmaceutical exports under the foreign trade policy. The implementation of the authentication system for drug formulations being exported will be undertaken by the Ministry of Health and Family Welfare in line with the provisions under Drug Rules 1945, according to a public notice of the Directorate General of Foreign Trade (DGFT). "The DGFT has decided to streamline export regulations by aligning with the evolving regulatory framework of the Ministry of Health & Family Welfare. Accordingly, the provisions related to the track and trace system for pharmaceutical exports under the Foreign Trade Policy are being withdrawn," the ministry said. The system, introduced on January 10, 2011, mandated barcoding at various packaging levels. While tertiary and secondary packaging requirements were successfully implemented in 2011 and 2013, primary-level barcoding and parent-child .

Cigna falls short of Q4 profit estimates due to higher medical costs

The plan, called "stop-loss insurance", entails the insurer covering for employers' self-funded plans when their costs surpass a certain threshold due to catastrophic or unexpected medical claims

Drugmaker Takeda's CEO Weber to step down, raises profit forecast

Julie Kim, president of the company's U.S. unit, was named to succeed Weber in June 2026

Granules India Q3FY25 results: Net profit drops 6% to Rs 118 crore

Drug firm Granules India on Friday said its consolidated profit after tax declined 6 per cent year on year to Rs 118 crore for the third quarter ended December 31, 2024. The company reported a profit after tax of Rs 126 crore in the October-December quarter of the last fiscal. Revenue from operations declined to Rs 1,138 crore in the third quarter as against Rs 1,156 crore in the year-ago period, the Hyderabad-based said in a regulatory filing. "We continue to sustain our profitable growth in the finished dosages segment, driven by our North America business. We are enhancing quality and compliance through systemic improvements across our operations, including Gagillapur," Granules India Chairman & Managing Director Krishna Prasad Chigurupati said. The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations. Subsequently, the production resumed in October in a staggered manner, it ...

Glenmark Pharma's US arm launches drug to treat blood clotting issues

According to IQVIA data for the 12-month period ending November 2024, the Vitamin K1 injectable emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million in the US